SG11201809007YA - Substituted fused pyrimidinone compounds - Google Patents

Substituted fused pyrimidinone compounds

Info

Publication number
SG11201809007YA
SG11201809007YA SG11201809007YA SG11201809007YA SG11201809007YA SG 11201809007Y A SG11201809007Y A SG 11201809007YA SG 11201809007Y A SG11201809007Y A SG 11201809007YA SG 11201809007Y A SG11201809007Y A SG 11201809007YA SG 11201809007Y A SG11201809007Y A SG 11201809007YA
Authority
SG
Singapore
Prior art keywords
torrent
bhat
dist
tal
gujarat
Prior art date
Application number
SG11201809007YA
Inventor
Chaitanya Dutt
Deepa Joshi
Milind Rode
Sanjay Srivastava
Davinder Tuli
Ramesh Gupta
Deepak Rai
Prashant Jamadarkhana
Shailesh Deshpande
Vivek Mishra
Jaya Abraham
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of SG11201809007YA publication Critical patent/SG11201809007YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/187324 Al 02 November 2017 (02.11.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: MAJUMDAR, Subhatosh et al.; S. Majumdar C07D 405/14 (2006.01) A61K 31/517 (2006.01) & Co., 5 Harish Mukherjee Road, State of West Bengal, CO7D 403/14 (2006.01) A61P 11/00 (2006.01) Kolkata 700 025 (IN). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/IB2017/052352 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 25 April 2017 (25.04.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 201621014526 26 April 2016 (26.04.2016) IN SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: TORRENT PHARMACEUTICALS LIMITED [IN/IN]; Torrent House, Off Ashram Road, Gu- (84) Designated States (unless otherwise indicated, for every jarat, Ahmedabad 380 009 (IN). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: DUTT, Chaitanya; Torrent Research Centre, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Tal & Dist. Gandhinagar, Gujarat, Bhat 382 428 (IN). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, JOSHI, Deep a; ; Torrent Research Centre, Tal & Dist. Gand-EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, hinagar, Gujarat, Bhat 382 428 (IN). RODE, Milind; Tor- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, rent Research Centre, Tal & Dist. Gandhinagar, Gujarat, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Bhat 382 428 (IN). SRIVASTAVA, Sanjay; Torrent Re-KM, ML, MR, NE, SN, TD, TG). search Centre, Tal & Dist. Gandhinagar, Gujarat, Bhat 382 = 428 (IN). TULI, Davinder; Torrent Research Centre, Tal Declarations under Rule 4.17: _ — & Dist. Gandhinagar, Gujarat, Bhat 382 428 (IN). GUP- — as to applicant's entitlement to apply for and be granted a TA, Ramesh, Chandra; Torrent Research Centre, Tal & patent (Rule 4.17(ii)) Dist. Gandhinagar, Gujarat, Bhat 382 428 (IN). RAI, Deep- — as to the applicant's entitlement to claim the priority of the ak; Torrent Research Centre, Tal & Dist. Gandhinagar, Gu earlier application (Rule 4.17(iii)) jarat, Bhat 382 428 (IN). JAMADARKHANA, Prashant; = = - Torrent Research Centre, Tal & Dist. Gandhinagar, Gujarat, Published: Bhat 382 428 (IN). DESHPANDE, Shailesh; Torrent Re- — with international search report (Art. 21(3)) = search Centre, Tal & Dist. Gandhinagar, Gujarat, Bhat 382 428 (IN). MISHRA, Vivek; Torrent Research Centre, Tal = & Dist. Gandhinagar, Gujarat, Bhat 382 428 (IN). ABRA- = HAM, Jaya; Torrent Research Centre, Tal & Dist. Gandhi- nagar, Gujarat, Bhat 382 428 (IN). = = = = (54) Title: SUBSTITUTED FUSED PYRIMIDINONE COMPOUNDS (57) : Provided herein are novel fused pyrimidinone derivatives of For- = ER 2],i mula (I) and synthetic intermediates that are useful in preparing the compounds of formula (I). Further provided herein is a method for preparation of a compound of formula (I) or intermediates, a pharmaceutical composition comprising a compound — Il .4 ei (R ']q ,X of formula (I), and use of a compound of formula (I) . 41:11 R 8 M _N IN R 5 GC \ Il R 6 IN Il R 3 Z lip [R 4 ] q 0 N (I) O
SG11201809007YA 2016-04-26 2017-04-25 Substituted fused pyrimidinone compounds SG11201809007YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621014526 2016-04-26
PCT/IB2017/052352 WO2017187324A1 (en) 2016-04-26 2017-04-25 Substituted fused pyrimidinone compounds

Publications (1)

Publication Number Publication Date
SG11201809007YA true SG11201809007YA (en) 2018-11-29

Family

ID=58745288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809007YA SG11201809007YA (en) 2016-04-26 2017-04-25 Substituted fused pyrimidinone compounds

Country Status (16)

Country Link
US (1) US20190127381A1 (en)
EP (1) EP3448855A1 (en)
JP (1) JP2019514906A (en)
KR (1) KR20180135486A (en)
CN (1) CN109071515A (en)
AR (1) AR108327A1 (en)
AU (1) AU2017256175A1 (en)
BR (1) BR112018072063A2 (en)
CA (1) CA3021542A1 (en)
EA (1) EA201892370A1 (en)
IL (1) IL262363A (en)
MX (1) MX2018012966A (en)
PH (1) PH12018502246A1 (en)
SG (1) SG11201809007YA (en)
TW (1) TW201806953A (en)
WO (1) WO2017187324A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN111269231B (en) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 Selective PI3K delta inhibitor and application thereof
CN116987085A (en) * 2022-04-26 2023-11-03 安徽中科拓苒药物科学研究有限公司 PI3K delta inhibitor and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760012B1 (en) 1997-02-26 2000-08-18 Oreal COMPOSITIONS FOR DYEING KERATINIC FIBERS CONTAINING PARA-AMINOPHENOLS, DYEING METHOD, NOVEL PARA-AMINOPHENOLS AND PREPARING METHOD THEREOF
MXPA03008560A (en) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Single-stage pfc + ballast control circuit/general purpose power converter.
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2619209A1 (en) * 2010-09-24 2013-07-31 Gilead Calistoga LLC Atropisomers of pi3k-inhibiting compounds
UY33337A (en) * 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES

Also Published As

Publication number Publication date
CN109071515A (en) 2018-12-21
EA201892370A1 (en) 2019-03-29
WO2017187324A1 (en) 2017-11-02
US20190127381A1 (en) 2019-05-02
BR112018072063A2 (en) 2019-02-12
TW201806953A (en) 2018-03-01
MX2018012966A (en) 2019-01-17
PH12018502246A1 (en) 2019-08-19
EP3448855A1 (en) 2019-03-06
IL262363A (en) 2018-11-29
CA3021542A1 (en) 2017-11-02
AU2017256175A1 (en) 2018-11-15
KR20180135486A (en) 2018-12-20
JP2019514906A (en) 2019-06-06
AR108327A1 (en) 2018-08-08
WO2017187324A9 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201408094YA (en) Neprilysin inhibitors
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201811161YA (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201407326XA (en) Compositions and methods for treatment of mucositis
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators
SG11201810389XA (en) New antibacterial compounds
SG11201903091VA (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors